About Event

Discovering the Future of Cell & Gene Therapy

This once-a-year meeting explores every aspect of in vivo cell and gene therapies, from selecting an appropriate animal model to discussing target specificity and unveiling strategies for advancing towards the clinic. Join C-level executives, VPs, and Directors in Discovery, Pre-Clinical, and Translational fields developing in vivo cell engineering and gene editing pipelines, as they converge to showcase various approaches, crystallize ambiguity, and ultimately advance pipelines to the next stage.

Agenda Highlights

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Optimizing target specificity to deliver payloads effectively with limited off-site toxicities with Argobio Studio, Editas Medicine, Mammoth Biosciences, and Primera Therapeutics

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Delving into the relationship between efficacy and toxicity to strike a balance with Mustang Bio and Vyriad Pharma

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Navigating different animal models such as humanized mice and non-human primate models to find the most suitable model for your studies with Sanofi and University of Massachusetts

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Assessing the different modes of delivery by showcasing both viral and non-viral mechanisms with Abintus Bio, Alaya.bio, Capstan Therapeutics, NanoCell Therapeutics, and Sanofi

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Understanding in vivo cell engineering beyond oncology into autoimmune indications to expand the therapeutic potential of treatments with Orna Therapeutics

3rd In Vivo Cell Engineering & Gene Editing Summit - Branding

Planning to scale from current pre-clinical stages into the clinic to gain insights from the closest companies with Capstan Therapeutics

Optimizing target specificity to deliver payloads effectively with limited off-site toxicities with Argobio Studio, Editas Medicine, Mammoth Biosciences, and Primera Therapeutics
Delving into the relationship between efficacy and toxicity to strike a balance with Mustang Bio and Vyriad Pharma
Navigating different animal models such as humanized mice and non-human primate models to find the most suitable model for your studies with Sanofi and University of Massachusetts
Assessing the different modes of delivery by showcasing both viral and non-viral mechanisms with Abintus Bio, Alaya.bio, Capstan Therapeutics, NanoCell Therapeutics, and Sanofi
Understanding in vivo cell engineering beyond oncology into autoimmune indications to expand the therapeutic potential of treatments with Orna Therapeutics
Planning to scale from current pre-clinical stages into the clinic to gain insights from the closest companies with Capstan Therapeutics

"I see the future of in vivo cell engineering is now finally being realized and this is going to transform how we can treat patients"
John Zuris, Director, Delivery & Editing Technologies, Editas Medicine

Download the Full Agenda for More Information on:

        • 15+ In Vivo Expert Speakers
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking
        • & Much More!

       

       

 

 

3rd In Vivo Cell Engineering & Gene Editing Summit - Full Agenda